文献速递免疫规划卫生政策与健康促进

巴西三州孕妇无细胞百日咳免疫的成本效果动态传播模型

Modeling the cost-effectiveness of maternal acellular pertussis immunization (aP) in different socioeconomic settings: A dynamic transmission model of pertussis in three Brazilian states.
PubMed 文献 · Vaccine · 2021-01-01

该研究用动态传播模型评估在巴西三个社会经济条件不同的州,为孕妇增加无细胞百日咳(aP)疫苗接种的健康与经济结果。结果显示孕妇aP免疫虽增加成本,但可挽救婴儿生命并减少伤残调整生命年(DALY),每避免一个DALY的增量成本在2022至3068美元之间。

要点

  • 孕妇aP免疫在三个社会经济条件不同的巴西州均具成本效果。
  • 每避免一个DALY的增量成本:圣保罗3068美元、巴拉那2962美元、巴伊亚2022美元。
  • 同一模型结构可拟合不同社会经济条件下的百日咳传播动态。

核心结论

  • 在巴西三个社会经济条件不同的州,孕妇接种aP疫苗联合婴儿wP接种具有成本效果。
  • 同一模型结构可代表不同社会经济条件下的百日咳疾病动态。

研究设计与样本

  • 研究使用动态传播模型,测试SIR、SIRS、SIRSIs三种模型结构拟合三个巴西州的数据。
  • 评估策略为仅婴儿wP接种对比孕妇aP免疫加婴儿wP接种,模型预测2014至2029年。

主要发现

  • SIRSIs模型拟合最佳,但相对SIRS模型统计定量评估改善有限。
  • 三个州中孕妇aP免疫均导致成本升高,同时挽救婴儿生命并避免DALY。
  • 每避免一个DALY的增量成本:圣保罗3068美元、巴拉那2962美元、巴伊亚2022美元。
  • 敏感性分析中,仅当百日咳病例报告概率假设高于基线时,增量成本效果比才超过人均地区生产总值。

关键数值与推荐

  • 成本以2014年美元计,视角为巴西国家卫生系统。
  • 模型预测包括门诊和住院百日咳病例、百日咳死亡、寿命损失年、DALY损失及成本。

临床怎么用

  • 可为孕妇接种aP疫苗作为婴儿百日咳防控的补充策略,在不同社会经济地区均可能具成本效果。

局限性

  • SIRSIs模型相对SIRS模型的统计定量评估改善有限。
  • 结果对百日咳病例报告概率的假设敏感。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Using dynamic transmission models we evaluated the health and cost outcomes of adding acellular pertussis (aP) vaccination of pregnant women to infant vaccination in three Brazilian states that represent different socioeconomic conditions. The primary objective was to determine whether the same model structure could be used to represent pertussis disease dynamics in differing socioeconomic conditions. METHODS: We tested three model structures (SIR, SIRS, SIRSIs) to represent population-level transmission in three socio-demographically distinct Brazilian states: São Paulo, Paraná and Bahia. Two strategies were evaluated: infant wP vaccination alone versus maternal aP immunization plus infant wP vaccination. Model projections for 2014-2029 include outpatient and inpatient pertussis cases, pertussis deaths, years of life lost, disability-adjusted life-years (DALYs) lost, and costs (in 2014 USD) of maternal aP vaccination, infant vaccination, and pertussis medical treatment. Incremental cost per DALY averted is presented from the perspective of the Brazilian National Health System. RESULTS: Based on goodness-of-fit statistics, the SIRSIs model fit best, although it had only a modest improvement in statistical quantitative assessments relative to the SIRS model. For all three Brazilian states, maternal aP immunization led to higher costs but also saved infant lives and averted DALYs. The 2014 USD cost/DALY averted was $3068 in Sao Paulo, $2962 in Parana, and $2022 in Bahia. These results were robust in sensitivity analyses with the incremental cost-effectiveness ratios exceeding per capita gross regional product only when the probability that a pertussis case is reported was assumed higher than base case implying more overt cases and deaths and therefore more medical costs. CONCLUSIONS: The same model structure fit all three states best, supporting the idea that the disease behaves similarly across different socioeconomic conditions. We also found that immunization of pregnant women with aP is cost-effective in diverse Brazilian states.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Luz PM, Struchiner CJ, Kim SY, et al. Modeling the cost-effectiveness of maternal acellular pertussis immunization (aP) in different socioeconomic settings: A dynamic transmission model of pertussis in three Brazilian states. Vaccine. 2021. PMID: 33303180. doi:10.1016/j.vaccine.2020.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。